Literature DB >> 20145226

Association between CYP2D6 polymorphisms and breast cancer outcomes.

Timothy L Lash.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20145226     DOI： 10.1001/jama.2010.92

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

Review 1.  Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.

Authors:  Deirdre P Cronin-Fenton; Timothy L Lash
Journal:  Expert Rev Clin Pharmacol       Date:  2011-05       Impact factor: 5.045

Review 2.  Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Authors:  Deirdre P Cronin-Fenton; Per Damkier; Timothy L Lash
Journal:  Future Oncol       Date:  2014-01       Impact factor: 3.404

3.  CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic.

Authors:  Issa Dahabreh; Teruhiko Terasawa; Peter Castaldi; Thomas A Trikalinos
Journal:  PLoS Curr       Date:  2010-09-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.